Safety Assessment, In Vitro and In Vivo, and Pharmacokinetics of Emivirine, a Potent and Selective Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1

Ähnliche Einträge

• Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase
  von: Sudbeck, Elise A., et al.
  Veröffentlicht: (1998)
• A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides
  von: Van Herrewege, Yven, et al.
  Veröffentlicht: (2004)
• Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
  von: Barnard, John P., et al.
  Veröffentlicht: (2019)
• Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor
  von: Ferris, Robert G., et al.
  Veröffentlicht: (2005)
• Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor
  von: Lai, Ming-Tain, et al.
  Veröffentlicht: (2009)